Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial. (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/jnnp-2018-320288
PubMed Identifier: 31315908
Publication URI: http://europepmc.org/abstract/MED/31315908
Type: Journal Article/Review
Volume: 90
Parent Publication: Journal of neurology, neurosurgery, and psychiatry
Issue: 10
ISSN: 0022-3050